Loading...
OTCM
ATTOF
Market cap4kUSD
Oct 05, Last price  
0.00USD
1D
0.00%
1Q
0.00%
Jan 2017
-100.00%
IPO
-100.00%
Name

Atento SA

Chart & performance

D1W1MN
OTCM:ATTOF chart
P/E
—
P/S
0.00
EPS
—
Div yield, %
—
Shrs. gr., 5y
23.96%
Rev. gr., 5y
-76.59%
Revenues
1m
-99.91%
2,290,500,0002,341,115,0002,298,324,0001,965,600,0001,757,498,0001,921,300,0001,818,200,0001,707,300,0001,412,300,0001,449,200,0001,350,000
Net income
-61m
L-32.79%
-679,440,000-4,039,000-42,152,00049,148,00065,000-16,800,00018,500,000-80,700,000-46,800,000-90,200,000-60,627,000
CFO
-59m
L
99,599,000135,295,00036,978,000141,946,000114,452,00081,200,00046,400,000128,200,00042,300,000-59,199,000
Dividend
Nov 09, 20170.3384 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.

Key people

Charles Sykes
Non-Executive Chairman of the Board · since 2024
Alexandre Mafra Guimaraes
Chief Financial Officer · since 2025
Kiomara Hidalgo
Chief People Officer · since 2021
Anil Bhalla
Executive Director · since 2024
Josh Ashby
Chief Delivery Officer · since 2021
Nick Delis
Chief Commercial Officer · since 2025
Virginia Trapero
Chief Legal Officer
Dimitirius de Oliveira
Chief Executive Officer, Director · since 2023
Mark Nelson-smith
Director · since 2023
John Chapman
Non-Executive Director · since 2024
John Madden
Independent Director · since 2020
Rober Payne
Independent Director · since 2022
Akshay Shah
Independent Director · since 2022
URL
https://atento.com/en/
IPO date
Oct 02, 2014
Employees
135,000
Domiciled in
LU
Incorporated in
LU

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT